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Background: There are multiple studies that have suggested the positive association between 
omega-3 fatty acid intake and the risk of cancer, however, there is a need to summarize and 
validate the evidence of the associations. 
Objective: We aimed to summarize and evaluate the evidence for the association between 
omega-3 fatty acid intake and cancer outcomes. 
Design: We searched PubMed from inception to December 1st, 2018 to conduct an umbrella 
review on meta-analyses of observational studies (cohort and case-control studies) that 
examined associations between omega-3 fatty acid intake and cancer risk (gastrointestinal, 
hepatobiliary, breast, gynecologic, prostate and brain/lung/skin). We determined the level of 
evidence of associations between omega-3 intake and the risk of the cancers. 
Results: We initially screened 598 articles, and 15 reviews with 52 meta-analyses were 
included. Among 52 meta-analyses, 13 reported statistically significant results, but no meta-
analysis showed a convincing or suggestive evidence of an association. While one meta-
analysis on skin cancer (n=1 of 3) was not assessible for determining the evidence, the other 
12 significant meta-analyses showed a weak evidence of omega-3 fatty acid intake and 
hepatobiliary cancer (n=4 of 6), breast cancer (n=3 of 14), prostate cancer (n=2 of 11) and brain 
tumor (n=2 of 2). 
Conclusion: Although omega-3 fatty acids have been studied in several number of meta-
analyses with regard to a wide range of cancer outcomes, only weak associations were 
identified in some cancer types with several limitations. In conclusion, we found limited 
evidence of protective effect of omega-3 fatty acid intake on cancer risk. 
 




Omega-3 fatty acids, also called n-3 fatty acids, play important roles in human health and 
a variety of diseases [1], and therefore, they are considered as one of the important resources 
for the human body. Omega-3 fatty acids include long-chain alpha-linolenic acid (ALA), 
eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) [2]. ALA is considered as an 
essential fatty acid because it cannot be synthesized by the body and must be obtained by 
consumption of food or supplements. However, as EPA and DHA are generated from ALA in 
the body, they are not considered as such [3]. Omega-3 fatty acids can be ingested from plant 
oil obtained from walnuts, flaxseed, and canola containing ALA [4]. EPA and DHA can be 
supplemented by eating fatty fish such as albacore tuna, salmon, mackerel, sardines, and 
herring [5]. Omega-3 fatty acids are incorporated in numerous parts of the body [6]. For 
example, DHA is a key component of all cell membranes [7] and EPA and DHA are precursors 
of metabolites that act as lipid mediators, assumed to be effective in preventing or treating 
several diseases [8]. 
The putative effects of omega-3 fatty acid supplementation on various cancer risks have 
been examined in numerous meta-analyses [9, 10]. However, these reviews have generated 
conflicting results and did not comprehensively appraised and considered biases and 
uncertainty in the body of the evidence to claim associations. In fact, hints biases have been 
identified in previous meta-research studies on cancer etiology. Recently, a new approach 
called umbrella review have been developed to investigate field wide evidence on complex 
topic such as cardiovascular diseases, cancers, and multiple health outcomes [11-13]. To the 
best of our knowledge, no umbrella review has investigated the association between omega-3 
and cancer risk. 
Given the aforementioned, we set out to provide an overview and evaluate the validity of 
reported associations of omega-3 fatty acids with various cancer risks, we performed the first 
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umbrella review of the evidence across existing systematic reviews and meta-analyses of 
observational studies. 
 
Materials and Methods 
Search strategy of the literatures 
We performed an umbrella review of the systematic reviews and meta-analyses on 
associations between omega-3 fatty acid intake and cancer risks. Three investigators (J.I.S., 
H.J.S. and E.K.C.) searched PubMed database and included the articles that have been 
published in English only. The last search was done on December 1st. We used the following 
search terms: (omega 3 fatty acid OR n-3 fatty acid OR w-3 fatty acid OR α-linolenic acid OR 
eicosapentaenoic acid (EPA) OR docosahexaenoic acid (DHA) OR polyunsaturated fatty acid 
(PUFA) OR docosapentaenoic acid (DPA) OR long chain polyunsaturated fatty acids 
(LCPUFA) OR fish OR fish oil OR krill oil) AND meta. We also excluded the articles by 
examining titles, abstracts, and full texts in order.  
 
Eligibility and inclusion/exclusion criteria 
We included only systematic review and meta-analyses that examined the association 
between omega-3 fatty acid and cancer risk. We excluded studies that (1) examined genetic 
polymorphisms related to omega-3 fatty acid metabolism; (2) had omega-3 fatty acid status as 
the outcome; (3) dealt with cost-effectiveness of omega-3 fatty acid supplementation; (4) meta-
analyses in which the treatment arm contained several compounds including omega-3 fatty 
acids; (5) meta-analyses focusing on the ratio of omega-3/ omega-6 PUFA; (6) not reporting 
cancer risk; (7) meta-analyses not about omega-3 fatty acids. We also excluded meta-
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regression analyses and sensitivity analyses. A detailed flow chart of screening and selection 
processes of eligible articles is presented in Figure 1. 
 
Extraction of the data 
Data were extracted by 3 investigators (G.K., H.P. and E.J.) and any discrepancy was 
discussed and resolved by consensus. For each eligible review, we gathered the outcome data 
of meta-analyses. We also abstracted and recorded the name of first authors, journal, 
publication year, type of outcome, types of patients, study design (cohort and/or case-control), 
the number of studies, type of metric (risk ratio, odds ratio and hazard ratio, as reported by the 
authors of the meta-analysis), effect size with the corresponding confidence intervals, meta-
analysis model (fixed/random), p-value for overall effects, I2 or χ2 for between-study 
heterogeneity, p-value for between-study heterogeneity and Egger’s p-value or other statistics 
for publication bias. 
 
Statistical re-analyses of the meta-analyses with statistically significant result under 
conventional criteria (p<0.05) 
With the extracted data from meta-analyses, we re-analyzed the meta-analyses showing 
statistically significant results (p<0.05). We collected all the included individual studies and 
performed the re-analysis using the software package Comprehensive Meta-Analysis 
(v.3.3.070). Then, we summarized different summary effect sizes with the corresponding 95% 
confidence intervals (CIs) from the results of meta-analyses. We applied random-effects 
models by assuming that individual effects of studies were different (i.e. between-study 
heterogeneity). We also calculated the 95% prediction interval (PI), which further accounts for 
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between-study heterogeneity and evaluates the uncertainty of the effect that would be expected 
in a new study addressing the same association [14-16]. 
We then assessed the heterogeneity between studies using I2, which ranges from 0 to 
100%, and the p-value of the χ2-based Cochran Q test [17]. I2 is the ratio of between-study 
variance over the sum of the within-study and between-study variance [18]. I2 values >50% or 
>75% are usually interpreted as having large or very large heterogeneity, respectively [18]. We 
also evaluated small-study effects to identify whether such studies tend to give much larger 
risk estimates than large studies [19]. By using the regression asymmetry test proposed by 
Egger and colleagues, we assessed small-study effects indicating publication and other 
reporting bias [20]. An Egger p-value of less than 0.10 in a random-effects model was judged 
to provide evidence for small-study effects. 
 
Level of evidence of associations  
Based on results of our re-analysis of statistically significant meta-analysis, we further 
grouped the associations between omega-3 fatty acids and cancer risks according to the 
conventional criteria [17, 21]: evidence of strong statistical significance using random-effects 
meta-analyses at p-value<0.01 (a threshold that has been suggested to substantially reduce the 
number of false positive findings) [22-24], magnitude of between-study heterogeneity (I2 
<50%), number of cases with binary outcomes > 1,000, absence of small study effects (Egger 
p-value ≥ 0.10) and 95% PI excluded the null. 
Non-significant associations had p-value >0.05.  
Weak evidence in which there is a large heterogeneity (I2>50%) or publication bias and 
evidence of small-study effects. Even though there is no large heterogeneity (I2>50%) or 
 10 
publication bias, small number of cases (number of cases<1,000) or a nominally significant 
association (p= 0.01-0.05) would be observed. 
Suggestive evidence required a significant association with p-value<0.01, the absence of 
large heterogeneity (I2<50%), absence of publication bias, 95% PI included the null, number 
of cases>1,000, and no evidence of small-study effects. If all other criteria except number of 
cases or total participants were satisfied, we classified the group as suggestive evidence. 
Convincing evidence required strong statistical significance in a meta-analysis with p-
value<0.01, the absence of large heterogeneity (I2<50%), no evidence for publication bias, 
number of cases with binary outcomes>1,000, no evidence of small-study effects, and 95% PI 
excluded the null. 
If a meta-analysis included only one study, the between-study heterogeneity and Egger p-
value was not available. In this case, we determined the level was not assessable (NA). 
 
Results 
Overall summary of meta-analyses 
Total of 598 articles were initially reviewed with exclusions of duplicated ones, and 15 
eligible articles with 52 meta-analyses were included in our review. We systematically 
categorized 52 meta-analyses into 6 cancer risk categories as follows: gastrointestinal cancer, 
hepatobiliary cancer, breast cancer, gynecologic cancer, prostate cancer and brain/lung/skin 
cancer [9, 25-38]. There were no eligible meta-analyses articles on leukemia, lymphoma, or 
hematologic malignancy. 
 
Gastrointestinal cancer outcomes 
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Among 4 meta-analyses identified from the literature search, all showed a statistically non-
significant association of cancer risk with omega-3 fatty acids intake. The studies were on 
gastric cancer (n=1) and colorectal cancer (n=3) (Table 1). 
 
Hepatobiliary cancer outcomes 
Six meta-analyses examined hepatobiliary-related. Among these, four meta-analyses were 
statistically significant, with reduction of cancer incidence with ometa-3 fatty acids intake. The 
other 2 results were not statistically significant (Table 2). 
 
Breast cancer outcomes 
Among 14 meta-analyses, 3 showed a statistically significant result for reduction of breast 
cancer risk with omega-3 fatty acids intake. The remaining meta-analyses showed no 
association (Table 3). 
 
Gynecologic cancer outcomes 
Among 10 meta-analyses, omega-3 fatty acids intake did not affect the incidence of 
ovarian cancer (n=5) or endometrial cancer (n=5) (Table 4). 
 
Prostate cancer outcomes 
Among 11 meta-analyses, three meta-analysis showed statistically significant results on 
association with risk of prostate cancer with omega-3 fatty acids intake (n=3). Of 3 results, one 
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meta-analysis showed that consumption of long chain n-3 increased the risk of prostate cancer 
(RR 1.14, 95% CI 1.01-1.28), whereas the other two meta-analyses found a protective effective 
of omega-3 intake. The remaining meta-analyses reported no association (n=8) (Table 5).  
 
Brain/lung/skin cancer outcomes 
Among 7 meta-analyses associated with brain, lung and skin cancer, three reported 
statistically significant associations. Two studies revealed a significant reduced incidence of 
brain tumors with omega-3 fatty acids intake (n=2 of 2). Also, a meta-analysis including one 
case-control study found a reduced risk of melanoma significantly. Contrary to the results 
above, there was no association between the role of omega-3 fatty acids in lung (n=2) and other 
skin cancer (n=2) (Table 6).  
 
Levels of evidence of association  
Of 13 significant associations, 12 studies were available to determine the level of evidence. 
One study on melanoma was not assessible since it contained only one individual study. Of 12 
associations, no study showed a convincing or suggestive evidence of association. All meta-
analyses with significance showed a weak evidence: hepatobiliary cancer (n=4 of 6), breast 
cancer (n=3 of 14), prostate cancer (n=3 of 11) and brain tumor (n=2 of 2). One meta-analysis 
showed statistically significant result, but the level of evidence was not applicable due to lack 
of included studies. The other 39 meta-analyses were non-significant. 
Among 12 meta-analyses with weak level of evidence, five (41.7%) had a nominally 
significant association (p=0.01-0.05). Four (33.3%) had I2>50%, implying large heterogeneity 
between studies, however, none of them showed very large heterogeneity (I2>75%). Regarding 
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publication bias, seven studies (58.3%) showed evidence of small study effects (Egger p-value 
< 0.10). (Table 7) 
 
Discussion 
Our umbrella review is the first to examine the evidence from meta-analyses of 
observational studies on the relationship between omega-3 fatty acid intake and cancer risk. 
Extensive data were provided by 15 eligible meta-analyses. Among these, we extracted meta-
analyses for primary or secondary outcomes, classified these meta-analyses according to types 
of outcomes, and evaluated each type of analysis with level of significance, using collected 
data (e.g., p for overall effect, p for heterogeneity, and I2, p for publication bias, prediction 
intervals and number of participants). As we classified the results into convincing, suggestive, 
weak, or non-significant evidence, all meta-analyses with significance showed a weak evidence, 
but no meta-analysis showed a convincing or suggestive evidence of an association. All 12 
meta-analyses for the effects of omega 3 intake on hepatobiliary cancer (n=4 of 6), breast 
cancer (n=3 of 14), prostate cancer (n=3 of 11) and brain tumor (n=2 of 2) showed statistically 
significant results with a weak evidence. One meta-analysis on skin cancer was also significant, 
but it only contained a single individual study, and the level of evidence was not assessible. As 
noted above, although some types of cancers showed that omega-3 intake may reduce the 
incidence or risk, the level of evidence was weak. Regarding the sources of omega 3 fatty acid, 
the studies were on total dietary fish intake (n=12, 23.1%), PUFA (n=18, 34.6%), ALA (n=9, 
17.3%), EPA (n=5, 9.6%), DHA (n=4, 7.7%) and DPA (n=3, 5.8%). This means that the 
sources of omega 3 intake are not a significant factor in cancer risk. 
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One study stated that there was a positive association between long-chain n-3 intake and 
risk of prostate cancer. However, it only included 2 individual cohorts, with p-value showing 
nominal significance (p=0.036), which should be interpreted cautiously. 
Our results found that few studies on omega-3 intake showed high levels of evidence. 
Thus, it will be important not to overemphasize the claimed associations by clarifying the 
evidence.  
Most clinicians focus only on the overall p-value to determine the significance of results. 
However, we should also consider the effect size, 95% CI, heterogeneity, publication bias, or 
funnel plot data [18, 19, 39]. Using a method that follows the conventional criteria, it is possible 
to establish the level of evidence much easily for multiple meta-analyses.  
An umbrella review is a type of meta-analysis designed to provide a conclusive summary 
of reports highlighting the level of evidence [40]. Since Ioannidis et al. first suggested the 
concept in 2009 [41], an increasing number of umbrella reviews have been published [41]. A 
single meta-analysis usually offers the misuse of inadequate statistical methods [41] and can 
result in misleading outcomes, distortion, and bias. Recently, the level of evidence has gained 
more importance to increase the value of the publication and provide an informative summary 
for decision makers in healthcare [40, 41].  
Most of the meta-analyses primarily presented their results with random- or fixed-effects 
size and 95% CI (with p-value). However, in order to determine the noteworthiness of the 
results, it was important to conduct further analysis of between-study heterogeneity and small 
study effects [17, 20]. 
Previously published meta-analyses mostly had a lack of information about publication 
bias, which made it difficult to assess the validity of the evidence synthesis [42]. In our study, 
24 of 52 meta-analyses did not mention the value for publication bias, which include three 
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statistically significant results. This limitation explains the need to comprehensively interpret 
the meta-analyses using an umbrella review. 
 The public considers omega-3 fatty acids to be beneficial for health, leading to the 
consumption of fish oil supplements. Reflecting this trend, much research has assessed the 
potential association of omega-3 fatty acids with health outcomes, with a special focus on 
reduction, which led to conflicting results. Nevertheless, no comprehensive study on omega-3 
fatty acids has specifically studied levels of evidence. Moreover, most recent evidence from a 
randomized controlled trial highlighted that supplementation with omega-3 fatty acids did not 
significantly lower the incidence of cancer, which supports our finding [10]. 
In addition, we compared our final result with the report from the Word Cancer Research 
Fund/American Institute for Cancer Research (WCRF/AICR). According to the latest report 
published from Continuous Update Project (CUP) initiated by WCRF/AICR, high amounts of 
fish consumption was significantly associated with reduction of liver and colorectal cancer, 
both graded as ‘limited – suggestive’ evidence [43]. However, studies of the other cancers 
including head and neck, lung, stomach, pancreas, gallbladder, ovary, endometrium, prostate, 
kidney, bladder and skin cancer draw a conclusion with ‘limited-no conclusion’ evidence. In 
our study, the meta-analyses assessing the risk of colorectal cancer were not significant, 
however, in case of liver cancer, there were a positive association supported by a weak level 
of evidence. Putatively, omega-3 fatty acids have an anti-inflammatory, which may lower risk 
for cancers, including liver and colorectal cancer [44, 45]. Nevertheless, the level of evidence 
was still limited, suggesting that the further studies are needed to confirm these findings. The 
lack of strong evidences regarding HCC may be partly explained also by the multifactorial 
etiology of such tumor type. Indeed, it may be possible that relevant biological differences in 
response to omega-3 fatty acid may exist in case of viruses-related neoplasms vs. HCC 
associated to peculiar environmental risk factors vs. others. 
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The mechanisms of cancer preventive effect of omega-3 fatty acids remain to be 
elucidated. There has been evidence for their effect on the immune system. An epidemiological 
study has shown that marine omega-3 fatty acids are associated with lower risk of colorectal 
cancer containing higher numbers of FOXP3+ regulatory T cells [46], corroborated by in vitro 
experimental evidence for their stimulating effect on CD4+ T cells via suppressing regulatory 
T cells [46]. 
In fact, one of possible reasons why there is only weak evidence for effects of omega-3 
fatty acids on overall organ-specific cancer risk is combining biologically heterogeneous 
cancer subtypes into one entity, which has been done in a vast majority of epidemiological 
studies. When there is a causal association only with a specific cancer subtype, an effect size 
is always larger for the specific subtype than for overall cancer containing all subtypes [47, 
48]. Weak or no evidence for risks of overall organ-specific cancers does not exclude causal 
associations for specific cancer subtypes [47, 48].  
There were some limitations in our study. First, we included studies from certain published 
meta-analyses and thus might have missed some individual studies if they were not identified 
with our pre-defined systematic search strategy. Second, we did not reanalyze all the data. 
Third, an original epidemiological study could be cited in two or more meta-analyses. Even 
though one meta-analysis that has better quality should be selected for one cause-response 
association and meta-analyses should be summarized in one-exposure-many-outcomes, or 
many-exposures-one-outcome associations in forest plots, small study numbers could not fully 
reflect these facts. Fourth, the degree or definitions of high or low omega-3 intake may across 
individual studies. Finally, we only investigated only the association of omega-3 intake on 
cancer risks. Further meta-research articles on a level or ratio of omega 3 fatty acid components 




In conclusion, although omega-3 fatty acids are commonly used as dietary supplements 
and many studies on omega-3 fatty acids have been published, there was no convincing 
evidence related to the effects of omega-3 fatty acids on cancer risk. Weak evidence supported 
the association between omega-3 fatty acids and breast cancer, hepatocellular carcinoma, 
prostate cancer, and brain tumor. The conclusion of no convincing evidence is limited to 
omega-3 uptake, not on mortalities or levels or ratios of omega-3: omega-6. For outcomes with 
suggestive or weak evidence, further studies are needed to identify the actual effects of omega-
3 fatty acids on cancer risks by individual patient data meta-analyses. In addition, subgroup 
analyses according to various factors, as well as elimination of bias and errors in big data or 
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effect size (95% 
CI) 





Wu (2011)            
Gastric cancer  17 
CC, 
Cohort 
High fish consumption 5323/136226 RR 0.87 (0.71, 1.07) Random NR 73.3 (<0.001) 0.59 No 
Shen (2012)            
Colorectal cancer  7 Cohort High ω -3 PUFAs intake 4656/489465 RR 0.97 (0.86, 1.10) Random NR 38.1 (0.08) NR No 
Chen (2015)            
Colorectal cancer  11 
CC, 
Cohort 
Marine n-3 PUFA intake (high 
vs. low) 
NR RR 1.00 (0.93, 1.07) Random NR 0.0 (0.51) 0.73 No 
Geelen (2007)            
Colorectal cancer  14 Cohort Fish consumption (high vs. low) NR RR 0.88 (0.78, 1.00) Random NR 18.3 (0.25) 0.66 No 


















size (95% CI) 





Huang (2015)            
HCC  10 
CC, 
Cohort 
High total fish intake 1984/5370040 RR 0.82 (0.71, 0.94) Random 0.018 12.8 (0.325) 0.07 Yes 
HCC 5 CC High total fish intake 809/10352 RR 0.79 (0.59, 1.06) Random 0.27 41.9 (0.142) NR No 
HCC 5 Cohort High total fish intake 1175/5359688 RR 0.82 (0.70, 0.96) Random 0.011 0.0 (0.487) NR Yes 












ALA intake 583/91291 RR 0.70 (0.30, 1.10) Random NR 0.0 (1.000) NA No 
Abbreviations: No., number; Random effects, summary effect size (95% CI) using random effects model; RR, risk ratio; CC, case-control; HCC, hepatocellular carcinoma; ALA, alpha-linolenic acid; PUFAs, 

















effect size (95% 
CI) 





Zheng (2013)            




Highest marine n-3 PUFA 
intake 
16178/527392 RR 0.86 (0.78, 0.94) Random NR 54 (0.003) 0.017 Yes 
Breast cancer 10 
Nest CC, 
Cohort 
Total n-3 PUFA NR RR 0.96 (0.86, 1.06) Random NR 13 (NR) 0.04 No 
Breast cancer 11 
CC, 
Cohort 
Marine n-3 PUFA(Diet) 11519/443619 RR 0.85 (0.76, 0.96) Random NR 67 (0.001) NR Yes 
Breast cancer 3 Cohort 
Per 0.1g/day increment of 
dietary marine n-3 PUFA 
3114/117488 RR 0.95 (0.90, 1.00) Random NR 52 (0.1) NR Yes 
Breast cancer 6 Cohort 
Per 0.1% energy increment of 
daily dietary marine n-3 PUFA 
6344/288626 RR 0.95 (0.90, 1.00) Random NR 79 (<0.001) NR No 




Highest dietary fish intake 13323/687770 RR 1.03 (0.93, 1.14) Random NR 54 (0.009) 0.6 No 
Breast cancer 14 
Nest CC, 
Cohort 
Per 15g/day increment of fish 
intake 
13323/666400 RR 1.00 (0.97, 1.03) Random NR 64.0 (0.001) NR No 




Marine n-3 fatty (EPA) NR RR 0.93 (0.85, 1.02) Random NR 2.9 (NR) NR No 




Marine n-3 fatty (DHA) NR RR 0.88 (0.75, 1.03) Random NR 37.6 (NR) NR No 




Marine n-3 fatty (DPA) 4746/284724 RR 0.90 (0.69, 1.19) Random NR 0.0 (NR) NR No 
Breast cancer 6 
CC, 
Cohort 
ALA(Diet) 8274/281756 RR 0.98 (0.90, 1.06) Random NR 5.1 (0.384) NR No 
Breast cancer 4 
CC, 
Cohort 
Per 0.1g/day increment of 
dietary ALA intake 
6310/190451 RR 0.99 (0.98, 1.01) Random NR 65.0 (0.035) NR No 
Breast cancer 3 Cohort 
Per 0.1% energy increment of 
daily dietary ALA intake 
5510/171680 RR 1.00 (0.99, 1.00) Random NR 0.0 (0.770) NR No 




ALA (Tissue biomarker and 
Diet) 
9296/284724 RR 0.97 (0.90, 1.04) Random NR 0.0 (0.548) 0.37 No 
Abbreviations: No., number; Random effects, summary effect size (95% CI) using random effects model; CC, case-control; RR, risk ratio; NR, not reported; ALA, alpha-linolenic acid; EPA, eicosapentaenoic 
acid; DHA, docosahexaenoic acids; PUFAs, polyunsaturated fatty acids; DPA, docosapentaenoic acid  
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effect size (95% 
CI) 





Hoang (2018)            
Endometrial cancer 5 
CC, 
Cohort 
Dietary omega-3 fatty acids 
(high vs. low) 
NR/159907 OR/HR 0.95 (0.72, 1.26) Random NR 67.3 (NR) NR No 
Endometrial cancer 4 
CC, 
Cohort 
EPA intake (high vs. low) NR /158999 OR/HR 0.86 (0.58, 1.30) Random NR 81.3 (NR) NR No 
Endometrial cancer  5 
CC, 
Cohort 
ALA intake (high vs. low) NR /159907 OR/HR 0.93 (0.81, 1.08) Random NR 0.0 (NR) NR No 
Endometrial cancer 4 
CC, 
Cohort 
DHA intake (high vs. low) NR /158999 OR/HR 0.89 (0.63, 1.28) Random NR 76.1 (NR) NR No 
Endometrial cancer 2 
CC, 
Cohort 
DPA intake (high vs. low) NR /88774 OR/HR 0.86 (0.71, 1.03) Random NR 0.0 (NR) NA No 
Ovarian cancer  3 CC 
Dietary omega-3 fatty acids 
(high vs. low) 
4269/5803 OR 0.79 (0.61-1.03) Random NR 74.5 (NR) NR No 
Ovarian cancer  2 CC EPA intake (high vs. low) 3238/3392 OR 0.89 (0.73, 1.08) Random NR 71.5 (NR) NA No 
Ovarian cancer  3 CC ALA intake (high vs. low) 4269/5803 OR 0.99 (0.77, 1.26) Random NR 58.6 (NR) NR No 
Ovarian cancer  2 CC DHA intake (high vs. low) 3238/3392 OR 0.91 (0.75, 1.11) Random NR 0.0 (NR) NA No 
Ovarian cancer  1 CC DPA intake (high vs. low) 1366/1414 OR 1.06 (0.85, 1.33) NA NR NA NA No 
Abbreviations: No., number; Random effects, summary effect size (95% CI) using random effects model; OR, odds ratio; HR, hazard ratio; NR, not reported; CC, case-control; ALA, alpha-linolenic acid; 

















effect size (95% 
CI) 





Fu (2015)            




Per 0.5g/day increase in ALA 
intake 
7781/430090 RR 0.99 (0.98, 1.00) Random -NR 0.0 (0.670) NR Yes 




Per 0.05g/day increase in EPA 
intake 
7778/450999 RR 1.02 (0.99, 1.05) Random NR 36.1 (0.181) NR No 
Szymanski (2010)            
Prostate cancer 12 CC High fish consumption 5777/9805 OR 0.85 (0.72, 1.00) Random 0.05 44 (0.05) 0.62 No 
Prostate cancer 12 Cohort High fish consumption 13924/445820 RR 1.01 (0.90, 1.14) Random 0.83 59 (0.005) 0.84 No 
Alexander (2015)            
Prostate cancer 13 Cohort High ω-3 PUFA intake (Diet) NR/446243 SRRE 1.00 (0.93, 1.09) Random NR 50.4 (0.019) NR No 
Chua (2012)            
Prostate cancer 4 Cohort ALA intake NR/177133 RR 0.92 (0.85, 0.99) Random 0.019 0 (0.677) 0.34 Yes 
Prostate cancer 2 Cohort Total omega 3 intake NR /93047 RR 0.97 (0.89, 1.07) Random 0.549 20 (0.264) NR No 
Prostate cancer 3 Cohort EPA intake NR /151326 RR 1.05 (0.96, 1.15) Random 0.317 41 (0.182) 0.65 No 
Prostate cancer 3 Cohort DHA intake NR /196192 RR 1.03 (0.94, 1.13) Random 0.489 52 (0.127) 0.54 No 
Prostate cancer 2 Cohort Long-chain n-3 NR /30731 RR 1.14 (1.01, 1.28) Random 0.036 25 (0.249) NA Yes 
Prostate cancer 4 Cohort Long-chain n-3 +(DHA+EPA) NR /82483 RR 1.03 (0.97, 1.10) Random 0.278 0 (0.462) 0.51 No 
Abbreviations: No., number; Random effects, summary effect size (95% CI) using random effects model; CC, case-control; OR, odds ratio; RR, risk ratio; SRRE, summary relative risk estimates; NR, not 
reported; NA, not assessible; ω, omega; ALA, alpha-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acids; PUFAs, polyunsaturated fatty acids  
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Lian (2017)            
Brain tumor 9 
CC, 
Cohort 
Fish intake (high vs. low) 4428/505296 RR 0.83 (0.70, 0.99) Random NR 37.5 (0.119) 0.02 Yes 
Brain tumor 9 
CC, 
Cohort 
Per 100g/week increase fish 
intakes 
4428/505296 RR 0.95 (0.91, 0.98) Random NR 51.7 (0.035) 0.02 Yes 
Zhang (2014)            
Lung cancer 11 Cohort PUFA intake (high vs low) NR/1268442 RR 0.91(0.78, 1.06) Random 0.230 67.7 (0.001) 0.186 No 
Lung cancer 11 Cohort 
PUFA intake (per 5g/day 
increment) 
NR/1268442 RR 0.98 (0.96, 1.01) Random 0.142 69.5 (<0.001) 0.135 No 
Noel (2014)            
Skin cancer, Basal cell 
carcinoma 







n-3 PUFA intake (high vs. low) NR/1890 RR 0.86 (0.59, 1.23) Random NR 52.6 (0.15) NA No 
Skin cancer, 
Melanoma 
1 CC n-3 PUFA intake (high vs. low) 304/609 OR 0.52 (0.34, 0.78) NA NR NA NA Yes 
Abbreviations: No., number; Random effects, summary effect size (95% CI) using random effects model; CC, case-control; OR, odds ratio; RR, risk ratio; NR, not reported; NA, not assessible; PUFA, 
polyunsaturated fatty acid 
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Liver cancer CC, Cohort High total fish intake 1984 <0.01 Not large Yes Excluded null Weak 




Fish consumption NR <0.01 Not large Yes Included null Weak 




Highest marine n-3 PUFA 
intake 
16178 <0.01 Large Yes Included null Weak 
Breast cancer CC, Cohort Marine n-3 PUFA (Diet) 11519 <0.01 Large Yes Included null Weak 
Breast cancer Cohort 
Per 0.1g/day increment of 
dietary marine n-3 PUFA 




Per 0.5g/day increase in 
ALA intakes 
7781 <0.05, but >0.01 Not large No Included null Weak 
Prostate cancer] Cohort ALA intake NR <0.05, but >0.01 Not large No Included null Weak 
Prostate cancer Cohort Long-chain n-3 NR <0.05, but >0.01 Not large NA NA Weak 
Brain tumor CC, Cohort Fish intake (high vs. low) 4428 <0.05, but >0.01 Not large Yes Included null Weak 
Brain tumor CC, Cohort 
Per 100g/week increase 
fish intakes 
4428 <0.01 Large Yes Included null Weak 
Abbreviations: No., number; CC, case-control; HCC, hepatocellular carcinoma; PUFA, polyunsaturated fatty acid; ALA, alpha-linolenic acid; NR, not 




Figure 1. Flow chart of the literature search 
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